Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Astellas and Vir Biotechnology Partner on $1.7B+ PRO-XTEN TCE Deal – VIR-5500 Targets PSMA in Prostate Cancer

Fineline Cube Feb 25, 2026
Company Deals

MGI Tech Sells Complete Genomics to Swiss Rockets for $50M – Divests US Unit to Mitigate Geopolitical Risks

Fineline Cube Feb 25, 2026
Company Deals

Junshi Biosciences Partners with Antengene on Cancer Combination – JS207 PD‑1/VEGF Bispecific Plus ATG‑037 CD73 Inhibitor

Fineline Cube Feb 25, 2026
Company Deals

Dartsbio Licenses PACAP Antibody DS009 to Slate Medicines – $130M Series A Fuels Global Migraine Development

Fineline Cube Feb 25, 2026
Company Deals

Henlius Licenses Serplulimab to Abbott for Emerging Markets – Expands Anti‑PD‑1 Global Footprint

Fineline Cube Feb 25, 2026
Policy / Regulatory

FDA Issues Draft Guidance on Plausible Mechanism Framework – Accelerates Approval Pathway for Individualized Genetic Therapies

Fineline Cube Feb 24, 2026
Company Drug

Dupixent Wins FDA Approval for Allergic Fungal Rhinosinusitis – First Targeted Therapy for AFRS Expands Dupilumab Label

Fineline Cube Feb 25, 2026
Company Drug

United Labs’ UBT251 Achieves 19.7% Weight Loss in Phase II – Triple‑Target GLP‑1/GIP/GCG Agonist Shows Blockbuster Potential

Fineline Cube Feb 25, 2026
Company Deals

Diagens Biotech’s AI Imaging Platform iMedImage Makes Hong Kong IPO Debut

Fineline Cube Jun 30, 2025

China-based Hangzhou Diagens Biotechnology Co., Ltd. has filed for an initial public offering (IPO) with...

Company Drug

Pfizer’s Emblaveo Approved by China’s NMPA for Complex Infections

Fineline Cube Jun 30, 2025

US giant Pfizer Inc., (NYSE: PFE) announced that it has received marketing approval from China’s...

Company Drug

Gilead’s Lenacapavir Approved in Hainan for HIV-1 Pre-Exposure Prophylaxis

Fineline Cube Jun 30, 2025

US-based Gilead Sciences, Inc. (NASDAQ: GILD) announced that its HIV pre-exposure prophylaxis (PrEP) drug, lenacapavir,...

Company Deals

GenFleet Therapeutics Files for Hong Kong IPO Amid KRAS Inhibitor Success

Fineline Cube Jun 30, 2025

China-based GenFleet Therapeutics (Shanghai) Inc. has submitted its initial public offering (IPO) application to the...

Company Deals

DK Medtech Partners with Mozarc Medical to Enhance Hemodialysis Access Solutions

Fineline Cube Jun 28, 2025

Suzhou-based DK Medical Technology Co. Ltd., a developer of vascular intervention balloon products, has entered...

Company Drug

ACIP Recommends MSD’s Enflonsia for Infants Under 8 Months to Prevent RSV

Fineline Cube Jun 27, 2025

US pharmaceutical giant Merck, Sharp & Dohme (MSD; NYSE: MRK) revealed that the Advisory Committee...

Others

Viatris Announces Positive Results in VEGA-3 Trial for MR-141 Presbyopia Treatment

Fineline Cube Jun 27, 2025

US-based Viatris (NASDAQ: VTRS) announced positive topline results from the second pivotal Phase III VEGA-3...

Company Medical Device

Jenscare’s LuX-Valve Plus Shows Promising Results in Global TRINITY Study

Fineline Cube Jun 27, 2025

Ningbo-based structural heart disease device maker Jenscare Scientific Co., Ltd (HKG: 9877) announced positive 30-day...

Company Drug

Innovent Biologics’ Mazdutide Gets NMPA Nod for Weight Management

Fineline Cube Jun 27, 2025

China’s National Medical Products Administration (NMPA) has approved Innovent Biologics, Inc.’s (HKG: 1801) mazdutide (IBI362),...

Company Deals

Mabwell Bioscience Partners With Calico Life Sciences on 9MW3811 Development

Fineline Cube Jun 27, 2025

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) is set to enter into a licensing...

Policy / Regulatory

China Raises Subsidy for Basic Public Health Services, Targets Vulnerable Groups

Fineline Cube Jun 27, 2025

China’s National Health Commission (NHC) released the “Notice on Improving Basic Public Health Services in...

Company Drug

Hua Dong Medicine’s HDM2020 Gains NMPA Approval for Clinical Trials

Fineline Cube Jun 27, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received clinical trial approval...

Company Drug

Cutia Therapeutics’ Phase III Results for Lidocaine-Tetracaine Cream to be Presented at CSD Meeting

Fineline Cube Jun 27, 2025

Cutia Therapeutics (HKG: 2487), a dermatology specialist, is set to present the Phase III clinical...

Company Deals

Novartis Completes Acquisition of Regulus Therapeutics for ADPKD Treatment

Fineline Cube Jun 27, 2025

Swiss giant Novartis (NYSE: NVS) announced the completion of its acquisition of U.S.-based Regulus Therapeutics....

Company Drug

Sino Biopharmaceutical’s LM-108 Gains CDE BTD for Gastric Adenocarcinoma

Fineline Cube Jun 27, 2025

Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has obtained Breakthrough Therapy Designation (BTD) from...

Company Deals

Mabwell Bioscience Grants Qilu Pharma Exclusive Rights to Mailisheng in Greater China

Fineline Cube Jun 27, 2025

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced a licensing agreement with compatriot firm...

Company Drug

Fosun Pharma’s Serplulimab Approved for ES-SCLC in the UK and India

Fineline Cube Jun 26, 2025

Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196, SHA: 600196) announced that its subsidiary Shanghai...

Company Drug

Sanofi’s Riliprubart Granted Orphan Drug Status for Antibody-Mediated Rejection Treatment

Fineline Cube Jun 26, 2025

France-based major Sanofi (NASDAQ: SNY) has secured Orphan Drug Designation (ODD) from the US Food...

Company Drug

Bio-Thera Solutions Initiates Phase III Trial of BAT8006 for Platinum-Resistant Ovarian Cancer

Fineline Cube Jun 26, 2025

Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced the successful first patient dosing in its Phase III...

Company

AstraZeneca Restructures to Form Gastrointestinal Oncology Business Unit

Fineline Cube Jun 26, 2025

UK major AstraZeneca (AZ, NASDAQ: AZN) this week reportedly unveiled a new organizational restructuring plan,...

Posts pagination

1 … 96 97 98 … 626

Recent updates

  • Dupixent Wins FDA Approval for Allergic Fungal Rhinosinusitis – First Targeted Therapy for AFRS Expands Dupilumab Label
  • United Labs’ UBT251 Achieves 19.7% Weight Loss in Phase II – Triple‑Target GLP‑1/GIP/GCG Agonist Shows Blockbuster Potential
  • Astellas and Vir Biotechnology Partner on $1.7B+ PRO-XTEN TCE Deal – VIR-5500 Targets PSMA in Prostate Cancer
  • Bio-Thera’s BAT4406F BLA Accepted by NMPA – Next‑Gen Anti‑CD20 mAb for Rare Disease NMOSD
  • MGI Tech Sells Complete Genomics to Swiss Rockets for $50M – Divests US Unit to Mitigate Geopolitical Risks
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Dupixent Wins FDA Approval for Allergic Fungal Rhinosinusitis – First Targeted Therapy for AFRS Expands Dupilumab Label

Company Drug

United Labs’ UBT251 Achieves 19.7% Weight Loss in Phase II – Triple‑Target GLP‑1/GIP/GCG Agonist Shows Blockbuster Potential

Company Deals

Astellas and Vir Biotechnology Partner on $1.7B+ PRO-XTEN TCE Deal – VIR-5500 Targets PSMA in Prostate Cancer

Company Drug

Bio-Thera’s BAT4406F BLA Accepted by NMPA – Next‑Gen Anti‑CD20 mAb for Rare Disease NMOSD

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.